Chemical industry – Page 105

  • Opinion

    A notable year for closures and layoffs

    2007-12-20T14:11:00Z

    It's been a rough year, but the future looks bright, says Derek Lowe

  • Business

    Business roundup: January 2008

    2007-12-20T13:59:00Z

    Manufacturing chemists face worldwide job cuts Bristol-Myers Squibb (BMS) has become the latest pharmaceutical company to announce a cost-saving restructuring plan that will slash manufacturing jobs. The US drug maker will scale down in its manufacturing operations, cutting its workforce by 4800 - about 10 per cent - ...

  • Opinion

    Is chemistry still valuable?

    2007-11-28T14:10:00Z

    Derek Lowe squares up to the challenge of biologics

  • Business

    Business roundup: December 2007

    2007-11-28T13:57:00Z

    Price fight over HIV drug GlaxoSmithKline has filed a lawsuit against Abbott Laboratories, claiming that its 2003 decision to increase the price of its HIV drug Norvir by 400 per cent was anticompetitive. GSK is the latest in a growing list of claimants to sue its US competitor, including four ...

  • Opinion

    Finding your flow

    2007-10-26T11:23:00Z

    Chemists are finally going with the flow, says Derek Lowe

  • Business

    Business roundup: November 2007

    2007-10-26T11:15:00Z

    Drug marketing case sees $500m settlement Bristol-Myers Squibb will pay over half a billion dollars to settle allegations of illegal drug marketing and pricing. The ruling, announced by the US Department of justice in late September, related to accusations that BMS had inflated its drug prices, paid kickbacks ...

  • Opinion

    The hidden benefit of higher energy bills

    2007-10-01T10:47:00Z

    The high cost of energy has an unexpected benefit, says Derek Lowe - it forces us to be more efficient

  • Business

    Business roundup: October 2007

    2007-10-01T09:58:00Z

    UK pharma shifts manufacturing overseas Anglo-Swedish drug firm AstraZeneca has restated its intention to outsource drug manufacturing ’where there is a sound business case’. The statement follows the publication of an interview with David Smith, AstraZeneca’s executive vice-president of operations, in The Times on 17 September. The newspaper ...

  • Opinion

    Zero justification

    2007-08-28T13:10:00Z

    Will Phase Zero trials actually help drug development, wonders Derek Lowe

  • Opinion

    Credit where it's due

    2007-07-26T11:07:00Z

    Process chemists just don't get the credit they deserve, says Derek Lowe

  • Business

    Business roundup: September 2007

    2007-07-26T10:51:00Z

    ICI sale finally agreed ICI have accepted a takeover offer of £8 billion from chemical conglomerate Akzo Nobel. This 670p per share agreement is Akzo’s third approach for ICI in as many months, following an initial offer of 600p per share in June, and then 650p per share in ...

  • Opinion

    Blinkers for bad news

    2007-06-29T12:51:00Z

    The Avandia controversy poses some tough questions about how to balance risks, says Derek Lowe

  • Business

    Business roundup: July 2007

    2007-06-29T12:45:00Z

    A depressing ruling for obesity drug A decision by a US Food and Drug Administration (FDA) advisory panel on 13 June was a double blow for French drug firm, Sanofi-Aventis. Their long-awaited obesity drug, rimonabant, marketed in Europe as Acomplia, was not recommended for approval by the FDA. ...

  • Opinion

    Patented fundamentals

    2007-05-24T12:34:00Z

    Derek Lowe sets the record straight about pharmaceutical patents on traditional medicines

  • Business

    Business roundup: June 2007

    2007-05-24T11:32:00Z

    FDA powers boosted by Senate Bill The US Senate has passed legislation to reinforce the authority of the Food and Drug Administration (FDA) to regulate drugs and medical devices. Under the legislation, there will be an increase in user fees that drugs companies and makers of medical devices ...

  • Business

    Business roundup: May 2007

    2007-04-27T09:41:00Z

    US chemical plant security legislation The US Department of Homeland Security (DHS) has released its final list of federal security regulations governing US chemical plants. The 2001 terrorist attacks in New York brought security measures under scrutiny, but with America on high alert many felt that chemical ...

  • Opinion

    Reasons to be cheerful

    2007-04-27T09:20:00Z

    After months of bleak news about faltering pipelines and redundancies, it's time to find reasons to be cheerful about the drug industry, says Derek Lowe.

  • Opinion

    Justifying total synthesis

    2007-03-28T11:39:00Z

    Derek Lowe wonders whether total synthesis is still worth the effort

  • Business

    Business roundup: April 2007

    2007-03-28T11:36:00Z

    Pharma’s house of cards Anglo-Swedish drug company AstraZeneca has announced plans to cut roughly 700 jobs at its site in Macclesfield, UK. A further 850 staff will go at Swedish production facilities. The news marks the first step in the implementation of the company’s plans to cut 3000 jobs from ...

  • Opinion

    Mergers: a cost-benefit analysis

    2007-02-28T15:15:00Z

    Do the benefits of pharmaceutical company mergers really outweigh the costs, asks Derek Lowe